Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iterum Therapeutics plcITRM · Entity 72802 | Director | November 18, 2025 | November 20, 2025 |
| Vaxart, Inc.AVIR · Entity 6654 | Director | May 18, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iterum Therapeutics plc
Report date November 18, 2025 · Filed November 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 241,001 |
Reported balance
After 2025-11-18 transaction · row 1
1 source rowRow 1 · 2025-11-18 · Purchase · Acquired 6,000 · Balance 241,001 |
Vaxart, Inc.
Report date May 18, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2027-05-18 | Direct | 75,000 |
Reported balance
After 2017-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-18 · Grant · Acquired 20,000 · Balance 75,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2025 Filed Nov 20, 2025 07:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 6,000 | $0.37 | $2,191.20 |
DisclosureSEC source: 0001193125-25-288848 · ownership.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,001 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 07:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 15,000 | $0.72 | $10,854.00 |
DisclosureSEC source: 0000950170-25-106908 · ownership.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,001 Read SEC document |
| August 06, 2024 Filed Aug 12, 2024 09:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionWarrants (right to buy) · Derivative | 106,247 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 4 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,247 Underlying: Ordinary Shares · 106,247 shares Expires 2029-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants"). Read SEC document |
| August 06, 2024 Filed Aug 12, 2024 09:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionWarrants (right to buy) · Derivative | 106,247 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 3 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,247 Underlying: Ordinary Shares · 53,123 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants"). Read SEC document |
| August 06, 2024 Filed Aug 12, 2024 09:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionSubscription Rights (right to buy) · Derivative | 212,494 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Units · Not disclosed shares Expires 2024-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.underlying_shares: The Reporting Person validly exercised 212,494 subscription rights to acquire 106,247 units composed of (i) 106,247 ordinary shares, (ii) 106,247 1-year warrants and (iii) 106,247 5-year warrants. Read SEC document |
| August 06, 2024 Filed Aug 12, 2024 09:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 106,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-095096 · ownership.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants"). Read SEC document |
| December 22, 2023 Filed Dec 27, 2023 09:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 25,000 | $1.40 | $35,000.00 |
DisclosureSEC source: 0001209191-23-059750 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,754 Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 16:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 10,000 | $1.84 | $18,442.00 |
DisclosureSEC source: 0001209191-23-059133 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,754 F1 · price: The price reported is a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $1.795 to $1.85. The Reporting Person undertakes to provide upon request of the SEC staff, the Issuer, or any shareholder of the Issuer, full information requiring the number of securities purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 17:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 20,000 | $2.03 | $40,690.00 |
DisclosureSEC source: 0001209191-23-056685 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,754 F1 · price: The price reported is a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $1.93 to $2.11. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2023 Filed Oct 2, 2023 09:20 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 3,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050911 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On December 23, 2022, the reporting person was granted an award of 3,487 RSUs, which vested in full on October 1, 2023. F2 · derivative.expiration_date: On December 23, 2022, the reporting person was granted an award of 3,487 RSUs, which vested in full on October 1, 2023. Read SEC document |
| October 01, 2023 Filed Oct 2, 2023 09:20 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 3,487 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-050911 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 08:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-040406 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On September 25, 2022, the reporting person was granted an award of 1,799 RSUs, which vested in full on July 1, 2023. F2 · derivative.expiration_date: On September 25, 2022, the reporting person was granted an award of 1,799 RSUs, which vested in full on July 1, 2023. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 08:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 1,779 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-040406 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 17:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 15,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037407 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,853 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F2 · derivative.expiration_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023. F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 17:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 15,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037407 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 1,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022422 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,299 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On June 25, 2022, the reporting person was granted an award of 1,299 RSUs, which vested in full on April 1, 2023. F2 · derivative.expiration_date: On June 25, 2022, the reporting person was granted an award of 1,299 RSUs, which vested in full on April 1, 2023. F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 1,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022422 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| April 01, 2023 Filed Jun 5, 2023 08:00 UTC Amendment | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 1,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034106 · doc4a.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · balance_after: This amendment is being filed solely to correct an error in the Amount of Securities Beneficially Owned Following Reported Transaction in the original Form 4, as filed on April 3, 2023. The Amount of Securities Beneficially Owned Following Reported Transaction on April 1, 2023, which were reported as 37,636, should have been reported as 37,635. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 18:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 761 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-001287 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On March 25, 2022, the reporting person was granted an award of 11,426 RSUs (the "RSU Grant"), which vested on January 1, 2023. F2 · derivative.expiration_date: On March 25, 2022, the reporting person was granted an award of 11,426 RSUs (the "RSU Grant"), which vested on January 1, 2023. F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 18:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-001287 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 21:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 3,487 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062871 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,487 Underlying: Ordinary Shares · 3,487 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023. Read SEC document |
| September 25, 2022 Filed Sep 27, 2022 21:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 1,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051416 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779 Underlying: Ordinary Shares · 1,779 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 18:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 10,000 | $2.22 | $22,200.00 |
DisclosureSEC source: 0001209191-22-049352 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,576 F1 · balance_after: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 19,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039706 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,488 Underlying: Ordinary Shares · 19,488 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 18:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 36,798 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039312 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,798 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F2 · derivative.exercise_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022. F2 · derivative.expiration_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 18:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 36,798 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-039312 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 17:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 237,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037937 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,795 Underlying: Ordinary Shares · 237,795 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 11,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021542 · doc4.xml · derivative · entry 3 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,426 Underlying: Ordinary Shares · 11,426 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit ("2022 RSU") represents the contingent right to receive one ordinary share upon vesting of a 2022 RSU. F4 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the 2022 RSUs shall vest in full on January 1, 2023. F4 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the 2022 RSUs shall vest in full on January 1, 2023. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 10,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021542 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted share units ("2021 RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the 2021 RSUs. F2 · derivative.exercise_date: On March 25, 2021, the reporting person was granted an award of 10,494 2021 RSUs, which vested on March 25, 2022. F2 · derivative.expiration_date: On March 25, 2021, the reporting person was granted an award of 10,494 2021 RSUs, which vested on March 25, 2022. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionOrdinary Shares | 10,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021542 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted share units ("2021 RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the 2021 RSUs. Read SEC document |
| July 25, 2021 Filed Jul 27, 2021 21:30 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantOrdinary Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-030223 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,355 F1 · shares: Consists of 80,000 ordinary shares received upon vesting of performance-based stock units ("PSUs") on July 25, 2021, which PSUs were subject to performance conditions that have been satisfied. PSUs convert into ordinary shares on a one-for-one basis. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:05 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Stock Units · Derivative | 36,798 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-025953 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,798 Underlying: Ordinary Shares · 36,798 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 17:33 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Stock Units · Derivative | 10,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-013822 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,494 Underlying: Ordinary Shares · 10,494 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 25, 2022. F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 25, 2022. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 19:32 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | SaleOrdinary Shares | 33,143 | $1.73 | $57,337.39 |
DisclosureSEC source: 0000899243-21-003519 · doc4.xml · nonDerivative · entry 2 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,355 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the PSUs. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 19:32 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantOrdinary Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003519 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,498 F1 · shares: Consists of 80,000 ordinary shares received upon vesting of performance-based stock units ("PSUs") on January 25, 2021, which PSUs were subject to performance conditions that have been satisfied. PSUs convert into ordinary shares on a one-for-one basis. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 16:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseWarrants (right to buy) · Derivative | 46,155 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0000899243-20-029501 · doc4.xml · derivative · entry 2 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,155 Underlying: Ordinary Shares · 46,155 shares Expires 2025-10-27 F1 · price: The reported securities were purchased in the Issuer's registered public offering on October 27, 2020 at a combined purchase price of $0.65 per ordinary share and warrant. Each ordinary share was purchased together with a warrant to purchase 0.75 of an ordinary share. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 16:15 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 61,540 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029501 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,498 F1 · price: The reported securities were purchased in the Issuer's registered public offering on October 27, 2020 at a combined purchase price of $0.65 per ordinary share and warrant. Each ordinary share was purchased together with a warrant to purchase 0.75 of an ordinary share. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 11:34 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0000899243-19-003972 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2029-02-14 F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of February 15, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:11 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 500 | $10.00 | $5,000.00 |
DisclosureSEC source: 0001209191-18-049884 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,958 Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 17:18 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 500 | $10.00 | $5,000.00 |
DisclosureSEC source: 0001209191-18-048708 · doc4.xml · nonDerivative · entry 2 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,458 Read SEC document |
| August 24, 2018 Filed Aug 28, 2018 17:18 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 500 | $10.00 | $5,000.00 |
DisclosureSEC source: 0001209191-18-048708 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,958 Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-2 Preferred Shares · Derivative | 2,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 7 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F3 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries B-1 Preferred Shares · Derivative | 4,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 6 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F2 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionSeries A Preferred Shares · Derivative | 12,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 5 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,730 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | PurchaseOrdinary Shares | 2,000 | $13.00 | $26,000.00 |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 4 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,458 Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 2,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 3 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,458 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 4,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 2 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. Read SEC document |
| May 30, 2018 Filed May 30, 2018 17:02 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | ConversionOrdinary Shares | 12,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer. Read SEC document |
| May 24, 2018 Filed May 29, 2018 17:21 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantStock Option (Right to Buy) · Derivative | 79,567 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033905 · doc4.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,567 Underlying: Ordinary Shares · 79,567 shares Expires 2028-05-23 F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of May 24, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
| May 18, 2017 Filed May 22, 2017 19:30 UTC | Vaxart, Inc. AVIR · Entity 6654 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.49 Strike: $0.49 | $9,800.00 |
DisclosureSEC source: 0001437749-17-009784 · rdgdoc.xml · derivative · entry 1 Dunne Michael W. · CIK 0001553593 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-18 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.